These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31314609)

  • 21. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
    Ljung RCR
    Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.
    Raso S; Hermans C
    Expert Opin Biol Ther; 2018 Jan; 18(1):87-94. PubMed ID: 29256333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.
    Mei B; Pan C; Jiang H; Tjandra H; Strauss J; Chen Y; Liu T; Zhang X; Severs J; Newgren J; Chen J; Gu JM; Subramanyam B; Fournel MA; Pierce GF; Murphy JE
    Blood; 2010 Jul; 116(2):270-9. PubMed ID: 20194895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.
    Iorio A; Blanchette V; Blatny J; Collins P; Fischer K; Neufeld E
    J Thromb Haemost; 2017 Dec; 15(12):2461-2465. PubMed ID: 29119666
    [No Abstract]   [Full Text] [Related]  

  • 27. Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B.
    Brennan Y; Curnow J; Favaloro EJ
    Expert Opin Biol Ther; 2018 Jan; 18(1):95-100. PubMed ID: 29172774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
    Mancuso ME; Mannucci PM
    Drug Des Devel Ther; 2014; 8():365-71. PubMed ID: 24729686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.
    Peng A; Kosloski MP; Nakamura G; Ding H; Balu-Iyer SV
    AAPS J; 2012 Mar; 14(1):35-42. PubMed ID: 22173945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simoctocog alfa for the treatment of hemophilia A.
    Morfini M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1573-1580. PubMed ID: 29050497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching to extended half-life products in Canada - preliminary data.
    Keepanasseril A; Stoffman J; Bouskill V; Carcao M; Iorio A; Jackson S;
    Haemophilia; 2017 Jul; 23(4):e365-e367. PubMed ID: 28548284
    [No Abstract]   [Full Text] [Related]  

  • 35. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.
    Versloot O; Iserman E; Chelle P; Germini F; Edginton AN; Schutgens REG; Iorio A; Fischer K;
    J Thromb Haemost; 2021 Aug; 19(8):1896-1906. PubMed ID: 34013558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.
    Coyle TE; Reding MT; Lin JC; Michaels LA; Shah A; Powell J
    J Thromb Haemost; 2014 Apr; 12(4):488-96. PubMed ID: 24843882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stretching time.
    Savage N
    Sci Am; 2015 Jan; 312(1):S8-10. PubMed ID: 25597117
    [No Abstract]   [Full Text] [Related]  

  • 39. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.
    Castaman G; Linari S
    Expert Rev Hematol; 2018 Jul; 11(7):567-576. PubMed ID: 29886751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.